



Miracle of Gastroretentive Drug Delivery Systems: Approaches for Treatment of Gastric Disorders and their Future Perspectives

Jitendra Gupta ^{a*}, Pawan Pandey ^a and Reena Gupta ^a

^a *Institute of Pharmaceutical Research, GLA University, Mathura-281406, U.P., India.*

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i60B34663

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/81173>

Review Article

Received 18 October 2021

Accepted 20 December 2021

Published 22 December 2021

ABSTRACT

Nearly half of the world's population suffers from *Helicobacter pylori* (H. pylori) and gastric disorders. It is the most common pathogenic bacteria that cause gastritis, gastroduodenal ulcer disease, and gastric cancer. Because short residence period, a narrow absorption window in the upper small intestine results in poor bioavailability with standard dosage forms. In addition, combination therapies develop antibiotics, undesirable responses, and poor patient compliance. Therefore, these drawbacks may overcome by Gastro-retentive drug delivery systems (GRDDs). A site-specific drug delivery system comes into force for boosting the therapeutic oral bioavailability, prolonging the residence site, effective medication through a small absorption window of GIT, and stimulating local effect in the stomach and duodenum. This review highlighted anatomy and physiology of gastric barrier, various GRDDS approach, merits, demerits for improving drug delivery, and future perspectives. Finally, this review may benefit researchers and industrialists working in this field.

Keywords: *H. pylori; gastroretentive; floating systems; gastritis; buoyancy.*

1. INTRODUCTION

The oral route is the most popular drug delivery administration due to the ease of administration [1]. In addition, the patient compliance and ease of administration make them readily available in the market and widely used delivery system [2]. However, the bioavailability of drugs in oral dose forms is affected by various circumstances. Although, this route has limitations, such as short gastric residence time (GRT) and requiring time for contents to enter the intestine, and reduced absorption [3]. Further, gastric retention has gotten attention due to quick gastric emptying time. Drugs with a short half-life are rapidly absorbed and easily removed from the bloodstream, thus requiring frequent dosing. Further, the limitation can be overcome by developing oral sustained-controlled-release formulations to modify drug release time; this slowly releases the medication in the Gastrointestinal tract (GIT) and maintains effective drug concentration in blood [4]. However, such oral drug delivery devices encounter physiological restriction during variable GRT showing the inadequate medicament release from the drug delivery system. Although it is essential to deliver the therapeutic drug at a specific site to maintain drug concentration, due to variable GRT, concentration in the bloodstream is altered.

Innovative drug delivery devices overcome the drawback of poor oral drug delivery as gastro-retentive dosage forms. Further, this increases the stay of the drug for an extended period in the stomach and increases the GRT of medicines, improving drug absorption. In addition to this, this further improves drug bioavailability, prolongs the drug release, reduces drug wastage at high pH. The prolonged gastric emptying approach also treats peptic ulcer patients and reduces GI side effects by modifying drug delivery release. In addition to this, it improves the GRT of drugs in the stomach [5].

Gastro-retentive drug delivery systems (GRDDs) effectively delivered weakly acidic drugs like domperidone and papaverine to enhance solubility and reduce the dose. In addition to this, the Gastro-resistant tablet dosage form intentionally delays drug release to allow the tablet to pass after some time from one part to another. Prolong-release delivery systems are modified-release systems that show delayed drug release. Enteric-coated system designed to combat the stomach acidic environment and

provide site-specific release of drugs in the intestine. Drugs like Proton pump inhibitors, H₂ blockers, insulin delivery, and NSAIDs are suitable candidates for preparing delayed release dosage forms [6].

GRDDs are fruitful approaches that prolong GRT, targeting site-specific drug release for local and systemic effects. Over the last few decades, GRDD approaches designed and developed and further includes: High density (sinking) systems that show retention in the bottom of the stomach [7], low density (floating) systems [8-10], mucoadhesive systems offer adhesion to stomach mucosa [11] and Swellable systems through the pyloric sphincter [12,13], super porous hydrogel systems [14], and magnetic systems [15]. This review highlights various GRDDs approaches and methodologies for site-specific delivery of drugs at controlled release.

2. NEED FOR GRDDS

- Drugs absorbed at a particular site only require that maximum drug reaches a particular site.
- Drugs absorbing from the proximal part of the GIT.
- Drugs show low solubility and degradation at basic pH and erratic gastric emptying time (GET).
- A local or sustained drug delivery system treats certain conditions [16].

2.1 Merits of GRDDS

- Drugs with narrow absorption window.
- Longer stomach residence time, useful for treatment of peptic ulcer.
- For improving the bioavailability of drugs like captopril, cyclosporine, ranitidine, ciprofloxacin, amoxicillin, and absorption from stomach.
- Improves patient compliance and therapeutic efficacy by reducing dosing frequency.
- Targeted therapy for local ailments in the upper GI tract and avoids first pass.
- GRDDs prolong drug release, utilized for stomach and small intestine disorders.
- Site-specific drug delivery and excellent accessibility.
- Rapid absorption shows good blood flow rates.
- Minimize mucosal irritation due to controlled release, e.g., NSAIDs.

- Decreased fluctuations in plasma drug concentration prevent adverse effects [17].

Further, a study highlights the importance of several patents reported where the development of GRDDS has shown significant improvements in drug delivery over conventional formulations. The gastro retentive pulsatile pharmaceutical delivery of Valsartan improves solubility and enhances residence time [18].

Another study suggested minocycline enhances bioavailability. In addition to this, this further reduces severe gastrointestinal side effects, such as reflux, vertigo, dizziness, and nausea [19]. Finally, another study highlights that biodegradable, multi-layered controlled release gastro-retentive dosage form of zaleplon provides adequate sleep maintenance and minimizes next-day residual consequences [20].

2.2 Demerits of GRDDS

- Floating dosage systems show limitations and require increased fluid content in the stomach to work efficiently.

- Due to contractile waves, the floating dosage form quickly swipes away in supine or sleeping posture. So, patients should avoid taking floating dosage forms before sleep.
- In an acidic environment, drugs with stability and low solubility irritate the gastric mucosa.
- Bio/mucoadhesive systems show a high turnover rate due to layered and soluble mucus.
- Bio-adhesive drug delivery systems show esophageal binding. In addition to this, the hydrogel-based swelling requires a longer time to swell.
- Upon multiple administrations, increased size drug delivery systems cause stomach hazards, resulting in permanent retention in the stomach [16,17].

3. GRDDS ACTING DRUGS

The gastro retentive drug delivery systems are suitable for the following types of drug therapy that helps in prolonging GRT, depicted in Fig. 1 [21-27], and their impact over conventional delivery, summarized in Table 1 [28].




Fig. 1. Drugs candidates for GRDDS

Table 1. Impact of Gastro-retentive drug delivery in comparison to Conventional [28]

Parameters discussed	CDDS effect	GRRDS effect
Patient compliance	Poorly controlled	Shows better control
Dose Dumping	Higher dose dumping	Risk is less
Drugs locally acting on stomach	Not useful	More significant
Toxicity	High susceptibility	Less susceptibility
Poorly water-soluble drugs (high pH)	Not useful	More significant
Drugs degradation (colon)	Not useful	More significant
Drugs with fast GIT Absorption	Not useful	More significant
Drugs less absorption (small Intestine)	Not useful	More significant

CDDS: Conventional drug delivery system, GRDDS: Gastro-retentive drug delivery system

4. ANATOMICAL AND PHYSIOLOGICAL BARRIERS FOR GRDDS

4.1 Stomach

The stomach, the leading site of gastric retention, physiology, and anatomy, plays a significant contribution during the formulation of GRDDS. It is present in the upper abdomen and leads to distension due to a meal. Further, it comes at a resting state with 25-50 ml [29]. It has three parts: fundus, body, and pylorus (antrum). The body works as a reservoir for unassimilated food; the proximal part consists of the fundus and the distal part responsible for propelling contents into the intestine [30].

4.2 Gastric Motility and Emptying of Food

Gastric emptying mainly happens during fed and fasted states, but the mortality pattern differs in both states. The inter-digestive cycle occurs every 2-3 hrs in a fasting state via the stomach

and small intestine, known as the inter-digestive myoelectric cycle of relocating myoelectric complex (MMC). Further divided into four phases, shown in Fig. 2 [31]. First, the activities occur during gastric emptying, shown in Table 2 [32-60].

- **Phase i:** Basal phase, 45-60 min duration, showing no or few contractions.
- **Phase ii:** Pre-burst phase, having a duration of 30-45 min, involves intermittent contractions with a gradual increase in intensity.
- **Phase iii:** Burst phase, with a duration of 5-15 min, short period severe contraction, affecting proximal and distal parts; also known as (housekeeper waves), involving undigested removal food from the fasted stomach.
- **Phase iv:** It has a duration of 0-5 min. It is a transition period between Phase III and Phase I, showing decreased movement till the beginning of the subsequent cycle [31].




Fig. 2. Various phases of inter-digestive myoelectric cycle of migrating myoelectric complex

Table 2. GRDDs of various drugs and their purpose

Drugs	Polymers	Method of preparation	GRDDs	Purpose of Study	Ref.
Ranitidine Hydrochloride	Sodium carboxy methyl cellulose, HPMC K-100	Osmotic method involves swelling and floating	Floating tablet	Optimized formulation, Batch IVA/CT3 showed 35 sec lag time and floated till 19hrs. Batch IV, showed desired release	[32]
Famotidine Calcium pectinate	HPMC K15M, polycarbophil and Carbopol	Gelatin-emulsion	Gel beads	Floating beads showed prolong release with copolymer and float up to 1 days.	[33]
Ciprofloxacin HCl	Sodium alginate and HPMC K15M	Direct compression	Floating tablet	Tablet float due to effervesce nature and sustained the drug release for prolong period	[34]
Ofloxacin	HPMC K100M and Isabgol husk	Wet granulation	Tablet	Swelling property of tablet indicated water holding capacity results in floating and provide sustain drug release up to 24 h	[35]
Propranolol HCl	HPMC (K4M)/(E15) LV, and HPC. Xanthan gum and sodium alginate	Direct compression	Floating tablets	Formulation containing HPMC K4 M, showed in-vitro release (92%, 18 h)	[36]
Norfloxacin	Xanthan gum and HPMC (K4M)/(K100M)	Wet granulation	Floating tablet	Due effervescent nature, table floated in gastric medium for prolong period and released the drug $94.3 \pm 1.5 \%$ (9 h) containing HPMC (K4M)	[37]
Furosemide	Polymethacrylates and Eudragit RL30D	Direct compression	Mini tabs	Combination of Polymethacrylates Eudragit RL30D, maintained buoyancy within acceptable time and drug release over a period of 12 h.	[38]
Metoclopramide HCl	Karaya gum, guar gum, HPMC (E15) alone and in combination with HPMC (K15M)	Direct compression	Floating-matrix tablets	Tablet floated up to 24 h without erosion and prolonged the drug release.	[39]
Pregabalin	Cross povidone and HPMC	Wet granulation and compaction	Swelling and non-floating effervescent tablet	Buoyancy behavior over 24 h sufficient for significant amount of drug release	[40]
Fluconazole	Eudragit RL and Eudragit RS	Spontaneous emulsification	Mucoadhesive nanoparticles	Mucoadhesive nanoparticles contain fluconazole once-a-day showed significant local antifungal against candidiasis in gastric medium	[41]

Drugs	Polymers	Method of preparation	GRDDs	Purpose of Study	Ref.
Gabapentin	Hydroxy ethyl cellulose (HEC)	Direct compression	Floating tablets	Matrix tablets containing gabapentin enhanced GRT (up to 12 h) and prolonged the drug release (99.75 percent, at 12 h).	[42]
Verapamil	MCC, Eudragit L30D 55 and Eudragit NE 30D	Wet granulation for pellet preparation	Floating capsules	Multiple-unit floating pellet dosage form delivered significantly drug than conventional tablet due to buoyancy effect.	[43]
Metoprolol Succinate	Sodium alginate, NaCMC	Direct compression	Floating tablets	Controlled release Metoprolol Succinate, showed floating (16 h)	[44]
Acyclovir	HPMC	Compressed coating	Magnetic depot tablets	Extracorporeal magnet prolonged the GRT and influenced the duration of absorption of drug.	[45]
Metronidazole	HPMC E5 and Hydroxypropyl cellulose Mf50, MC, Carbopol 934P and κ-carrageenan	Ionotropic gelation	Chitosan-treated alginate beads	Beads showed 92.09% entrapment efficiency and immediate buoyancy behaviour results in drug release (100% after 4 h), and completely eradicate <i>H. pylori</i> .	[46]
Clarithromycin	HPMC (K4M)	Wet granulation	Floating tablets	Floating behaviour up to 12 h of tablets indicated increase in GRT and localized action of drug for Peptic ulcer due to <i>H. pylori</i> infection.	[47]
Amoxicillin	Gellun gum	In-situ gelation	In-situ gel solution	Prolongs ten times drug release	[48]
Silymarin	HPMC (K4M)/(K15M) and psyllium husk	Wet granulation	Floating tablets	Provides drug release up to 24hrs	[49]
Riboflavin	Eudragit S 100	Emulsion solvent diffusion	Micro-balloons	Micro-balloons showed inverse relationships between the buoyancy and the level of release of riboflavin from it.	[50]
Diltiazem HCL	Eudragit S 100 and Ethyl cellulose (EC)	Non-aqueous emulsion Solvent evaporation	Floating microspheres	Drug loaded mucoadhesive floating microspheres using calcium carbonate (gas generating agent) help in floating and released the Drug up to 8 h.	[51]

Drugs	Polymers	Method of preparation	GRDDs	Purpose of Study	Ref.
Aceclofenac	Eudragit S 100.	Emulsion dehydration	Floating microspheres	Floating microspheres coated with Eudragit- pectin delivered aceclofenac (24 h with significant anti-inflammatory effect) in colon for treatment of rheumatoid arthritis	[52]
Cimetidine	HPMC and EC	Solvent evaporation	Floating microspheres	Microspheres prolonged drug release (8 h), buoyancy for 10hr	[53]
Cephalexin	EC	Emulsion Solvent	Floating microspheres	Results showed stirring speed and polymer concentration affected with size and prolonged the drug release and floating time of more than 12 h	[54]
Metoprolol Tartrate	HPMC (K4M)/(K100M)	Direct Compression	Floating tablets	The floating tablets extended drug release up to 8 h, increased the gastric retention and to improve the bioavailability of the drug	[55]
Stavudine	HPMC (K4M)/(K15M)/ (K100K) and EC	Melt Granulation	Floating Matrix Tablet	Matrix system of hydrophobic and hydrophilic polymer decreased the burst release of drug from the floating tablet (floating time less than 3 min) and prolonged the drug release upto12 h.	[56]
Valacyclovir Hydrochloride	EC	Solvent Evaporation and Water-In-Oil Emulsification	Floating Microspheres	Floating microspheres prolonged the drug release 94.03% at 12h and localizing the drug at upper GIT.	[57]
Venlafaxine Hydrochloride	Carbopol 971P, EC, Eudragit RS-PO	Direct Compression	Mucoadhesive Tablets	Mucoadhesive tablet having adhesion time up to 12hours showed better GI residence and 99.85% drug release at 12 h	[58]
Metformin	HPMC (K4M), EC	Solvent Evaporation	Floating Micro-balloons	Floating microballoons exhibited excellent floatability (>10 h) and prolonged drug release(8h).	[59]
Ciprofloxacin Hydrochloride	Sodium Alginate, HPMC (K15M)	Direct Compression	Floating Matrix Tablets	Floating Matrix Tablets exhibited excellent floating behaviour (5.5 h), and sustained the drug release.	[60]

5. FACTORS AFFECTING GASTRIC RETENTION TIME OF THE GRDDS [61]

The following are the factors which affect the stability and performance of GRDDs.

- **Density of Dosage form:** Good floating property is often exhibited by the dosage forms having a thickness less than that of gastric fluids (~1.004g/ml). In contrast, a density closer to 2.7g/ml is needed for high-density systems to achieve good gastro-retention.
- **Size of the Dosage form:** Due to larger particle size, the dosage form having a diameter of more than 7.5mm, shows more GRT because it does not quickly pass from the pyloric antrum to the intestine.
- **Shape of the Dosage form:** Ring and tetrahedron shaped devices show significant gastro retention than other shapes. These devices with a 22.5-48 KSI (keto pound/ inch²) deliver more GRT (90-100%).
- **Fed or Unfed State:** GI motility characterized through MMC occurs every 1.5 to 2 hours, responsible for sweeping unprocessed material from the stomach. In addition to it, if it coincides with the drug administered along with MMC, GRT is predicted to be short during the unfed state. However, MMC delay during the fed state, and GRT is considerably longer.
- **Nature of Meal:** Consumption of fatty acids like starch and cellulose, indigestible polymers, changes stomach motility pattern and delays MMC. This further decreases gastric emptying rate (GER) and prolongs the drug release.
- **Caloric Content:** Protein-rich and fat diet increases GRT to 4 to 10h.
- **Frequency of Meal:** GRT improved more than 6 to 7 h with continuous meals compared to a single meal because of the low frequency of MMC.
- **Age:** People (age more than 70 years) have significant longer GRT, although GRT is less in children and new born infants.
- **Gender:** Males showed less GRT (3.4h) than female counterparts (4.6h).
- **Posture:** No significant effect of posture was found on GRT for individuals in the upright, ambulatory, and supine state
- **Concomitant Drug Administration:** Anticholinergic drugs like atropine, propantheline, and opiate-like codeine can prolong GRT.
- **Circadian Rhythms:** During the daytime, cardiac rhythms are increased, and night rhythms are less, affecting GRT.
- **Diseased State:** Pathological conditions like ulcers, spasm, and flatulence affects the GIT environment.
- **Exercise:** Retards gastric emptying time [61].

6. GASTRIC RETENTION APPROACHES

GRDDs concept was described in early 1962 and shows less bulk density than gastric fluids, so it stays in the stomach longer. Due to the buoyancy effect on the gastric contents, the drug liberated slowly, showing increased GRT and controlled plasma drug concentration. In addition, the device forms a cohesive gel barricade and maintains specific gravity less than gastric contents (1.004-1.010), discussed in (Table 3 and Figs. 3 and 4 (A-E)) [62-84].

Table 3. GRDDs approaches, methods and polymers for delivery

Approaches	Description	Polymers /Excipients	Ref.
Hydrodynamically balanced systems (HBS)	Drugs are added in combination with hydrocolloids, provides floating	Contains hydrophilic polymers Polycarbophil, Alginic acid sodium carboxymethyl cellulose, HPMC, agar and Polyacrylates	[62]
Raft systems	Carbonate due to chemical reaction, forms bubbles, provides floating	Sodium alginate, Sodium bicarbonate, Acid neutralizer.	[63-65]
Bio-adhesive/ Mucoadhesive systems	Bio-adhesive systems forms electrostatic bonds at stomach interface.	Bio-adhesive polymers like Sucralfate, dextrin, HPMC and Tragacanth	[66]
High density	Based on hypothesis, dense pellets	Barium sulphate, zinc	[67-69]

Approaches	Description	Polymers /Excipients	Ref.
systems	remain for longer duration	oxide and Fe are used	
Swelling type system	Swelling systems provides swelling property increases GRT	Biodegradable polymers and Swelling agents like Sodium starch glycolate and cross povidone	[70-72]
Magnetic systems	External stimuli as magnetic field used for targeted drug delivery	-	[73,74]
Hollow microspheres/ Microballoons	Useful for prolonged release containing captured air as microspheres, promotes floating	Poly D and PVA	[75-77]
Floating microspheres	Useful for prolonged release containing captured air as microspheres, promotes floating, increases GRT	Poly(acryl)starch, DEAE cellulose and Poly(acryl) dextran	[78,79]
Microporous Compartment System	Drug pool enclosed within compartment with pores, trapped air promotes floating and buoyancy in stomach	Cellulose, PVP, MC, PVA and HPMC	[80,81]
Alginate beads	Floating alginate linear anionic block Co-polymer shows hydrogel formation inotropic gelation, showing retention more than 5.5 h	Sodium and Calcium alginate and Low Methoxylated pectin	[82-84]







Fig 3. GRDDS approaches for delivery of drugs.




A. Hollow microspheres approach




B. Swelling System approach



C. Hydrodynamically balanced system approach



D. Muco-adhesive system approach



E. Floating system approach

Fig. 4. Drug release from various approaches of GRDDS (A-E)

7. FUTURE PERSPECTIVES

The rationale for GRDDS and its importance in industries are discussed in Fig. 5 [85-86], along

with the list of patents and marketed formulation of GRDDS showing prolonged residence time in Table 4 [87-123] and Table 5.




Fig. 5. GRDDS Rationale for selection of Drugs

Table 4. Patents on GRDDS and their approaches

Patent No.	Formulation	Approaches	Publication year	Ref.
US 4767627	GRDDs for controlled delivery of drugs	Swelling drug delivery showed control release.	1988	[87]
US 5443843	GRDDs drug for controlled release of drug	Shows more retention attached to controlled release device prevent GI transit.	1995	[88]
US 5780057	Tablet showing increased contact with gastric fluids	Two- or three-layer tablet, swells rapidly After imbibition prolongs GRT allows slow drug release	1998	[89]
US 597289	GRDDs for controlled release of sparingly soluble drugs	Tablets or capsules once ingested, swells and release the drug slowly	1999	[90]
US 6488962	Tablet shapes to enhance gastric retention	Specifically shaped oral swellable dosage forms, resist GI transit	2002	[91]
US 6548083	Prolonged release used for gastric retention	Polymer matrix, and swells and comes in contact with gastric fluids, increases the retention in stomach.	2003	[92]
US 6635280	GRDDs involving extended drug release in fed state	Diffusion method is used for release of polymer and dosage remains intact for longer duration until drug release	2003	[93]
US 2723340	Optimal polymer mixtures for gastric retentive tablets	Swelling facilitates controlled release of drug and gastro-retention	2004	[94]
US 6776999	Expandable GR therapeutically active system with a prolonged GRT	Drug release depends upon medicament form and not on polymer, prolongs GRT	2004	[95]
US 7976870	GRDDs showing with restricted drug release in lower GIT	Biocompatible polymers swell and erode rapidly, prolongs GRT, drugs release at controlled rate	2011	[96]
US 9393205	GR tablets	Monolithic tablets cause imbibition of gastric fluids, tablet floats, drug release is controlled	2016	[97]
US 9801816	GR dosage form for extended release of acamprosate	Acamprosate showed extended release due to swelling and erosion	2017	[98]
US 5769638	Buoyant controlled release powder formulation	Capsules floats and releases drug at controlled rate	1992	[99]
US 5198229	Self-retaining GIT delivery device	Drug delivery device with low density delivers the drug and provides floating in stomach	1993	[100]
US 5232704	Sustained release bilayer buoyant dosage form	Capsule made of non-compressed bi-layer promotes controlled release and floats in GI	1993	[101]
US 5626876	Floating system for oral therapy	Floatable and oral lighter than the gastric fluid is used, provides floating	1997	[102]
US 6207197	Gastro-retentive controlled release microspheres	Microsphere containing an active ingredient controls rate of drug release	2001	[103]
US 8277843	Programmable buoyant delivery technology	Drug-coated over coat is used, forms hollow space, provides programmable drug delivery	2012	[104]

Patent No.	Formulation	Approaches	Publication year	Ref.
US 8808669	GR extended-release composition of the therapeutic agent	Controlled release, shows floating and swelling effect at acidic condition, prolongs drug release	2014	[105]
US 9314430	Floating GR dosage form	Cylindrical shaped elongated form is used, shows floating	2016	[106]
US 9561179	Controlled-release floating pharmaceutical compositions	Microparticles containing drug deposited on floating core surface, shows control release	2017	[107]
US 5472704	Pharmaceutical CR composition with bio-adhesive properties	Mucoadhesive agents used for different routes like rectal, periodontal, vaginal, nasal, and ocular	1995	[108]
US 5900247.	Mucoadhesive pharmaceutical composition for the controlled release	Bio-adhesion facilitates the prolonged release in the buccal cavity	1999	[109]
US 6303147	Bio-adhesive solid dosage form (SDF)	Bio-adhesive shows prolonged release for locally or systemically acting drugs.	2001	[110]
US 6306789	Mucoadhesive granules of carbomer suitable for oral administration of drugs	Mucoadhesive granules, provides sustained release of the drug	2001	[111]
US 8974825 A	pharmaceutical composition for gastrointestinal drug delivery	Bio-adhesion promotes controlled release.	2015	[112]
US20050063980A1	Gastric raft composition	Floating raft promotes controlled release	2005	[113]
US00677700B2	In situ gel formation of pectin	In situ formation of floating raft, promotes release	2004	[114]
US6635281	The gastric retaining liquid dosage form	Bio-erodible carrier facilitates retention of within stomach, erodes rapidly	2003	[115]
US6797283	Gastric retaining dosage form having multiple layers	Multilayered active agent shows swellable properties, promotes controlled release	2004	[116]
US8586083	GRDDS comprising an extruded hydratable polymer	Involves extrusion, improved gastric retention.	2013	[117]
US9119793	GR dosage form of doxycycline	Combination of floating, swelling and bio-adhesive promotes drug release.	2015	[118]
US20150366832	GR dosage form for carbidopa/levodopa	Carbidopa Shows swelling properties.	2015	[119]
US20150231084	Osmotic floating tablets	Outer osmotic core achieves gastro-retention.	2015	[120]
US20160338949	Stabilized gastro-retentive tablets of pregabalin	Gastro-retention increased due to swelling	2016	[121]
EP3148514	The expandable gastro-retentive dosage form	Unfolding increases GRT and prolong release	2017	[122]
EP2575798	Gastro-retentive systems of GABA analogs	Swelling act as a release retardant	2017	[123]

Table 5. Marketed formulation of GRDDs

Brand Name	Active Ingredient	Dosage Form & Route	Manufacturer
Valrelease	Diazepam	Capsule, extended release	Roche Laboratories
Madopar	Benserazide and L-dopa	Dispersible Tablets, Per oral (P.O.)	Roche Laboratories
Liquid Gaviscon	Alum. Hydroxide and MgCO ₃	Liquid, P.O.	GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
Topalkan	Alum.-Mg antacid	SDF, P.O.	Pierre Fabre Drug, France
Conviron	Ferrous Sulphate	SDF, P.O.	Conviron
Cytotech	Misoprostol	SDF, P.O.	Pfizer
Cifran OD	Ciprofloxacin	SDF, P.O.	Sun pharmaceutical industries ltd
Glumetza	Metformin	SDF, P.O.	Salix Pharmaceuticals
Coreg CR	Carvidilol Phosphate	SDF, P.O.	Sun pharm industries
Inon Ace Tablets	Simethicone	SDF, P.O.	Sato Pharmaceutical Co., Ltd.
Almagate flatcoat	Aluminium magnesium antacid	Floating liquid form, P.O.	Pierre Fabre Drug, France
Cefaclor LP	Cefaclor	SDF, P.O.	
Baclofen GRS	Baclofen	SDF, P.O.	Sun pharm indu Stries
Zanocin OD	Ofloxacin	SDF, P.O.	Sun pharm industries
Coreg CR	Carvedilol	Gastro-retention with osmotic system (SDF), P.O.	GlaxoSmithKline
Inon Ace Tables®	Simethicone	Foam based floating system, P.O.	Sato Pharma, Japan
Prazopress XL®	Prazosin hydrochloride	Effervescent and swelling based floating system, P.O.	Sun Pharma, Japan
Accordion Pill®	Carbidopa/levodopa	Expandable system (unfolding), P.O.	Intec Pharma, Israel
Xifaxan®	Rifampicin	Bio-adhesive tablets, P.O.	Lupin, India
proQuin XR	Ciprofloxacin	Polymer based swelling technology: AcuForm™, P.O.	Depomed, USA

SDF: Solid dosage form

8. CONCLUSION

Gastro retentive drug delivery offers potential advantages in delivering drugs at enhanced solubility and bioavailability. On the other hand, the drawbacks of poor solubility, bioavailability, and high first-pass effect promote ideas for designing newer techniques for improving drug delivery at a controlled rate. In recent years, the Gastro retentive drug delivery system has been explored to ensure optimized drug delivery. Newer technologies adopted in GRDD offer swellable, absorbable, floating, and high-density systems, promoting the controlled release. In addition, it offers to improve patient compliance and promote industrial growth. GRDDs will provide newer leads that promote improved efficiencies for various pharmacotherapeutics in the coming future.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENTS

Authors thankful Institute of Pharmaceutical Research, GLA University, Mathura, U.P., India, for providing facilities to complete the article.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner E, Friedman M. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. *Int J Pharm.* 2004;277(1-2):141–153.
- Suvakanta D, Padala NM, Lilakanta N, Prasanta C. Kinetic modeling on drug release from controlled drug delivery systems. *Acta Pol Pharm.* 2010;67(3):217-223.
- Applied Biopharmaceutics and Pharmacokinetics, 7e, Access Pharmacy, McGraw Hill Medical. Accessed December 22, 2021. Available:<https://accesspharmacy.mhmedical.com/book.aspx?bookID=1592>
- Ma N, Xu L, Wang Q, Zhang X, Zhang W, Li Y, et al. Development and evaluation of new sustained-release floating microspheres. *Int J Pharm.* 2008;358(1-2):82-90.
- Sharma AR, Khan A. Gastro-retentive drug delivery system: An approach to enhance gastric retention for prolonged drug release. *Indian J Pharm Sci.* 2014;5(4): 1095-1106.
- Gupta P, Kesh M. Formulation and evaluation of gastroretentive floating tablets. *Int J Pharm.* 2018;6:1.
- Rouge N, Allémann E, Gex-Fabry M, Balant L, Cole TE, Buri P, et al. Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. *Pharm Acta Helv.* 1998;73(2):81–87.
- Streubel A, Siepmann J, Bodmeier R. Multiple unit gastroretentive drug delivery: A new preparation method for low density microparticles. *J Microencapsul* 2003; 20:329-347.
- Goole J, Vanderbist F, Aruighi K. Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms. *Int J Pharm.* 2007; 334:35-41.
- Sharma S, Pawar A. Low density multiparticulate system for pulsatile release of meloxicam. *Int J Pharm.* 2006;313:150-158.
- Santus G, Lazzarini G, Bottoni G, Sandefer Ep, Page Rc, Doll Wj, et al. An in vitro- in vivo investigation of oral bioadhesive controlled release furosemide formulations. *Eur J Pharm Biopharm.* 1997;44:39-52.
- Klausner Ea, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. *J Control Release.* 2003;90:143-162.
- Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. *Pharm Res.* 1997;14(6):815-819.
- Park K. Enzyme-digestible swelling as platforms for longterm oral drug delivery: Synthesis and characterization. *Biomaterials.* 1988;9:435-441.
- Fujimori J, Machida Y, Nagai T. Preparation of a magnetically-responsive tablet and configuration of its gastric residence in beagle dogs. *STP Pharma Sci.* 1994;4:425-430.
- Garg S, Sharma S. Gastroretentive drug delivery systems. *Business Briefing: Pharmatech.* 2003;160-166.
- Joseph RR, Vincent H, Lee L. *Controlled drug delivery, fundamentals and applications*, 2nd Ed, Revised and Expanded, New York: Marcell. Dekker Inc., 2009. Available:<https://doi.org/10.1177%2F088391159200700306>
- Gupta J, Gupta R, Vanshita. Microneedle technology: An insight into recent advancements and future trends in drug and vaccine delivery. *Assay Drug Dev Technol.* 2021;19(2):97-114.
- Bakan DA, Jitraphai W, Newhard SB, Wortzman MS. Gastroretentive dosage forms for minocycline. *US95611241*; 2017. Accessed on 15 October 2021.
- Masri S, Moor E, Kirmayer D, Kluev E, Carni G, Navon N. Zaleplon gastroretentive drug delivery system. *US9693981B2*; 2017. Accessed on 15 September 2021. Available:<https://patents.google.com/patent/US9693981B2/en>

21. Murphy CS, Pillay V, Choonara YE, du Toit LC. Gastroretentive drug delivery systems: current developments in novel system design and evaluation. *Curr Drug Deliv.* 2009;6(5):451-460.
22. Abourehab, Mohammed AS., Khaled AK, Hatem AS, Osama AA. Evaluation of combined famotidine with quercetin for the treatment of peptic ulcer: In vivo animal study. *Drug Des Devel Ther.* 2015;9:2159-2169.
<https://www.semanticscholar.org/paper/Evaluation-of-combined-famotidine-with-quercetin-of-Abourehab-Khaled/db283a4be053640e8054f72b6891842393c4e8b6>
23. Liu Q, Fassihi R. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. *Int J Pharm.* 2008;348(1-2):27-34.
24. Navon N, Julia S, Eytan M, David K, Elena K, Shuher M, et al. Baclofen and R-Baclofen gastroretentive drug delivery systems. US20110091542A1; 2011. Accessed 21 September 2021. Available:<https://patents.google.com/patent/US20110091542A1/en>
25. Gupta J, Ahuja A, Gupta R. Green approaches for cancer management: an effective tool for health care. *Anticancer Agents Med Chem*; 2021. DOI: 10.2174/1871520621666210119091826
26. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. *Eur J Pharm Sci.* 2003;18(1):37-45.
27. Streubel, A, Siepmann J, Bodmeier R. Floating microparticles based on low density Foa Powder. *Int J Pharm.* 2002;241(2):279-292.
28. Badoni A, Ojha A, Gnanarajan G, Kothiyal P. Review on gastro retentive drug delivery system. *J Pharm Innov.* 2012;1(8):32-40.
29. Campbell I. The mouth, stomach and intestines. *Anaesth Intensive Care Med.* 2012;13(2):56-58.
30. Arunachalam A, Karthikeyan M, Konam K, Prasad HP, Sethuraman S, Ashutoshkumar S. et al. Floating drug delivery systems: A review. *Int J Res Pharm Sci.* 2011;2(1):76-83.
31. Marinaganti RK, Bonthu S, Nagakanyaka DP, Sheik M, Deepthi P, Spandana V, et al. Comprehensive review on gastro retentive drug delivery system. *Acta Chim Pharm Indica.* 2013;3(2)149-164.
32. Kumar P, Singh S, Mishra B. Gastroretentive drug delivery system of ranitidine hydrochloride based on osmotic technology: Development and evaluation. *Curr Drug Deliv.* 2008;5(4):332-342.
33. Satheeshbabu B, Sarvaiya G. Gastroretentive drug delivery system of famotidine: Formulation and in vitro evaluation of oil entrapped calcium pectinate gel beads. *Indian J Pharm Sci.* 2016;78(2):203-209.
34. Tadros MI. Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: Development, optimization and *in vitro*-*in vivo* evaluation in healthy human volunteers. *Eur J Pharm Biopharm.* 2010;74(2):332-339.
35. Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. *Int J Pharm.* 2006;316(1-2):86-92.
36. Jagdale SC, Agavekar AJ, Pandya SV, Kuchekar BS, Chabukswar AR. Formulation and evaluation of gastroretentive drug delivery system of propranolol hydrochloride. *AAPS Pharm Sci Tech.* 2009;10(3):1071-1079.
37. Bomma R, Naidu RAS, Rao MY, Veerabrahma K. Development and evaluation of gastroretentive norfloxacin floating tablets. *Acta Pharm.* 2009;59(2):211-221.
38. Meka L, Kesvana B, Naidu VK, Eaga CM, Bandari S, Vobalaboina V, et al. Design and evaluation of polymeric coated minitables as multiple unit gastroretentive floating drug delivery systems for furosemide. *J Pharm Sci.* 2009;98(6):2122-2132.
39. Singh S, Singh J, Muthu MS, Balasubramaniam J, Mishra B. Gastroretentive drug delivery system of metoclopramide hydrochloride: Formulation and in vitro evaluation. *Curr Drug Deliv.* 2007;4(4):269-275.
40. Kim S, Hwang K, Park YS, Nguyen T, Park E. Preparation and evaluation of non-effervescent gastroretentive tablets containing pregabalin for once-daily administration and dose proportional pharmacokinetics. *Int J Pharm.* 2018;550(1-2):160-169.

41. Rençber S, Karavana SY, Yılmaz FF, Eraç B, Nenni M, Özbal S, et al. Development, characterization, and in vivo assessment of mucoadhesive nanoparticles containing fluconazole for the local treatment of oral candidiasis. *Int J Nanomedicine*. 2016; 11:2641.
42. Bhise MR, Jain DS, Shukla DK, Burakale DP, Sudke DSG. Formulation and in-vitro evaluation of floating tablet of gabapentin. *The J Orient Res Madras*. 2021; XCII(V):326-337.
43. Sawicki W. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. *Eur J Pharm Biopharm*. 2002;53(1):29-35.
44. Boldhane S, Kuchekar B. Development and optimization of metoprolol succinate gastroretentive drug delivery system. *Acta Pharm*. 2010;60(4):415-425.
45. Gröning R, Berntgen M, Georgarakis M. Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporeal magnets to control gastrointestinal transit. *Eur J Pharm Biopharm*. 1998;46(3):285-291.
46. Ishak RAH, Awad GAS, Mortada ND, Nour SAK. Preparation, in vitro and in vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-*Helicobacter pylori* therapy. *J Control Release*. 2007;119(2):207-214.
47. Nama M, Gonugunta CSR, Veerareddy PR. Formulation and evaluation of gastroretentive dosage forms of clarithromycin. *AAPS PharmSciTech*. 2008;9(1):231.
48. Rajinikanth PS, Balasubramaniam J, Mishra B. Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of *Helicobacter pylori*. *Int J Pharm*. 2007;335(1-2):114-122.
49. Garg R, Gupta GD. Preparation and evaluation of gastroretentive floating tablets of silymarin. *Chem Pharm Bull*. 2009;57(6):545-549.
50. Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. In vivo evaluation of riboflavin-containing microballoons for floating controlled drug delivery system in healthy human volunteers. *J Control Release*. 2003;93(1):39-47.
51. Pathak K, Kumar M, Patel NS. Optimization of diltiazem hydrochloride loaded mucoadhesive floating microspheres using calcium carbonate as gas generating agent as floatation aid. *Indian J Pharm Edu Res*. 2014;48(3):60-74.
52. Ramasamy T, Ruttala, HB, Shanmugam S, Umadevi SK. Eudragit-coated aceclofenac-loaded pectin microspheres in chronopharmacological treatment of rheumatoid arthritis. *Drug Deliv*. 2013; 20(2):65-77.
53. Srivastava AK, Ridhurkar DN, Wadhwa S. Floating microspheres of cimetidine: Formulation, characterization and in vitro evaluation. *Acta Pharm*. 2005;55(3):277-285.
54. Vasava K, Rajesh K, Jha LL. Formulation and evaluation of floating microspheres of cephalexin. *Int J Pharm Sci Rev Res*. 2011;11(2):69-75
55. Brahmaiah B, Bhagath GP, Gudipati M. Formulation and evaluation of gastroretentive floating drug delivery system of metoprolol tartarate. *Int J Life Sci Biotechnol Pharma Res*. 2013;2:183-197
56. Prajapati PH, Nakum VV, Patel CN. formulation and evaluation of floating matrix tablet of stavudine. *Int J Pharm Inv*. 2012;2:83-89.
57. Goswami N, Joshi G, Sawant K. Floating microspheres of valacyclovir HCl: Formulation, optimization, characterization, in-vitro and in-vivo floatability studies. *J Pharm Bioallied Sci*. 2012;4(5):S8-S9.
58. Zate SU, Kothawade PI, Rathi MN, Shitole MH, Yewale CP, Gawande VS. Development and characterization of gastroretentive mucoadhesive tablets of venlafaxine hydrochloride. *Int J Drug Deliv*. 2010;2:299-303.
59. Yadav A, Jain DK. Gastroretentive microballoons of metformin: formulation development and characterization. *J Adv Pharm Technol Res*. 2011;2(1):51-55.
60. Tadros Mi. Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: Development, optimization and in vitro-in vivo evaluation in healthy human volunteers. *Eur J Pharm Biopharm*. 2010;74(2):332-339.
61. Pahwa R, Singh M, Kumar V, Kohli K. Recent advances and patent perspectives in gastroretentive technology. *Recent Pat Drug Deliv Formul*. 2012;6(3):278-290.
62. Reddy LH, Murthy RSR. Floating dosage systems in drug delivery. *Crit Rev Ther Drug Carrier Syst*. 2002;19(6):553-585.

63. Iannuccelli, V, Coppi G, Sansone R, Ferolla G. Air compartment multiple-unit system for prolonged gastric residence. Part II. In vivo evaluation. *Int J Pharm.* 1998;174(1):55-62.
64. Foda, NH, Ali SM. Gastroretentive drug delivery systems as a potential tool for enhancing the efficacy of antibiotics: A review. *Int J Pharm Bio Sci.* 2011;2(2)94-104.
65. Nasa P, Mahant S, Sharma D. Floating Systems: a novel approach towards gastroretentive drug delivery Systems. *Int J Pharm Pharm Sci.* 2010; 2(3):1-7.
66. Moes AJ. Gastroretentive dosage forms. *Crit Rev Ther Drug Carrier Syst.* 1992;10(2):143-195.
67. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: A review with special emphasis on floating drug delivery systems. *Drug Deliv.* 2011;18(2):97-110.
68. Kumar AS. Gastro retentive drug delivery systems: An overview. *Pharminfo Net* [Online]. 2008.6. Accessed on 14 October 2021.
69. Garg R, Gupta GD. Progress in controlled gastroretentive delivery. *Trop J Phar Res,* 2008;7(3):1055-1066.
70. Nayak AK, Malakar J, Sen KK. Gastroretentive drug delivery technologies: Current approaches and future potential. *J Pharm Edu Res.* 2010;1(2):1-12.
71. Arza RAK, Gonugunta CSR, Veerareddy PR. Formulation and evaluation of swellable and floating gastroretentive ciprofloxacin hydrochloride tablets. *AAPS PharmSciTech.* 2009;10(1):220-226.
72. Chen RN, Ho HO, Yu CY, Sheu MT. Development of swelling/floating gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for Losartan and its clinical relevance in healthy volunteers with CYP2C9 polymorphism. *Eur J Pharm Sci.* 2010;39(1-3):82-89.
73. Oth M, Franz M, Timmermans J, Möes A. The bilayer floating capsule: A stomach-directed drug delivery system for misoprostol. *Pharm Res.*1992;9(3):298-302.
74. Whitehead L, Collett JH, Fell JT. Amoxicillin release from a floating dosage form based on alginates. *Int J Pharm.* 2000;210(1):45-49.
75. Patil C. Bakliwal S, Rane B, Gujarathi N, Pawar S. Floating microspheres: A promising approach for gastric retention. *Int J Curr Pharm Res.* 2011;2(12):26-38.
76. Krögel I, Bodmeier R. Development of a multifunctional matrix drug delivery system surrounded by an impermeable cylinder. *J Control Release.* 1999;61(1-2):43-50.
77. Crotts G, Park TG. Preparation of porous and nonporous biodegradable polymeric hollow microspheres. *J Control Release.* 1995;35(2):91-105.
78. Tanwar YS, Ojha G, Chauhan CS, Naruka, P. Floating microspheres: Development, characterization and applications. *Pharmainfo net* [Online]. 2006;4(3):1-7.
79. Taneja R, Kataria MK, Bilandi A, Gupta A, Gedar S. Floating microsphere: A potential gastroretentive drug delivery system. *Pharmacie Globale.* 2013;4(4):1-9
80. Harrigan, RM. Drug delivery device for preventing contact of undissolved drug with the stomach lining. US4055178A; 1977. Available: <https://patents.google.com/patent/US4055178A/en>
81. Vyas S, Khar RK. Gastroretentive systems. Controlled drug delivery. Delhi: Vallabh Prakashan, India. 2006:197-217.
82. Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. *Trop J Pharm Res.* 2008;7(3):1055-1066.
83. Lee KY, Mooney DJ. Alginate: Properties and biomedical applications. *Prog Polym Sci.* 2012;37(1):106-126.
84. Whitehead L, Collett JH, Fell JT. Amoxicillin release from a floating dosage form based on alginates. *Int J Pharm.* 2000;210(1-2):45-49.
85. Kawatra M, Jain U, Ramana J. Recent advances in floating microspheres as gastro-retentive drug delivery system: A review. *Int J Recent Adv Pharm Res.* 2012;2:5-23.
86. Nayak AK, Ruma M, Das B. Gastroretentive drug delivery systems: A review. *Asian J Pharm Clin Res.* 2010;3(1):2-10.
87. Caldwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US4767627A; 1988. Accessed on 9 October 2021. Available:<https://patents.google.com/patent/US4767627A/en>

88. Curatolo WJ, Lo W. Gastric retention system for controlled drug release. US5443843A; 1995.
Available:<https://patents.google.com/patent/US5443843A/en>
89. Conte U, Maggi L. Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids. US5780057; 1998.
Accessed on 9 October 2021.
Available:<https://patents.google.com/patent/US5780057A/en>
90. Shell JW, Louie HJ. Gastric-Retentive, Oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter. US5972389; 1999.
Accessed on 9 October 2021.
Available:<https://patents.google.com/patent/US5972389A/en>
91. Berner B, Louie HJ. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms. US6488962; 2002.
Accessed on 9 October 2021.
Available:<https://patents.google.com/patent/US6488962B1/en>
92. Wong PL, Dong LC, Edgren DE, Theeuwes F, Gardner PI, Jao F, et al. Prolonged release active agent dosage form adapted for gastric retention. US6548083B1; 2003.
Accessed on 9 October 2021.
Available:<https://patents.google.com/patent/US6548083B1/en>
93. Shell JW, Louie-Helm J, Markey M. Extending the duration of drug release within the stomach during the fed mode. US6635280; 2003.
Accessed on 9 October 2021.
Available:<https://patents.google.com/patent/US6635280B2/en>
94. Gusler G, Berner B, Chau M, Pagua A. Optimal polymer mixtures for gastric retentive tablets. US6723340; 2004.
Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US6723340B2/en?q=US6723340>
95. Krumme, M. Expandable gastroretentive therapeutical system with prolonged stomach retention time. US6776999; 2004.
Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US6776999B1/en?q=US6776999>
96. Berner B, Louie-Helm J, Shell JW. gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract. US7976870; 2011.
Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US7976870B2/en?q=US7976870>
97. Kumar V, Ahmad S, Singh RM. Gastroretentive Tablets. US9393205; 2016.
Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US9393205B2/en?q=US9393205>
98. Berner B, Chen C. Gastric retentive dosage forms for extended release of acamprostate into the upper gastrointestinal tract. US9801816; 2017.
Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US9801816B2/en?q=US9801816>
99. Dennis A, Dimmins P, Lee K. Buoyant controlled release powder formulation. US5769638; 1992.
Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US5769638A/en?q=US5769638>
100. Wong P, Theeuwes F, Larsen SD. Self-retaining gastrointestinal delivery device. US5198229; 1993.
Accessed on 10 October 2021.
Available:<https://patents.justia.com/patent/5198229>
101. Franz MR, Oth MP. Sustained release bilayer buoyant dosage form. US5232704; 1993.
Available:<https://patents.google.com/patent/US5232704A/en>
102. Muller W, Anders E. Floating system for oral therapy. US5626876; 1997.
Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US5626876A/en>
103. Illum L, Ping H. Gastroretentive Controlled release microspheres for improved drug delivery. US6207197.
Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US6207197B1/en>
104. Singh A, Singh S, Puthli S, Tandale R. Programmable buoyant delivery technology. US8277843; 2012.
Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US8277843B2/en>
105. Muthusamy R, Kulkarni SG. Gastroretentive, extended-release composition of therapeutic agent. US8808669; 2014.

- Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US8808669B2/en>
106. Grenier P, Nhamias A, Veergnault G. Floating gastric retentive dosage form. US9314430; 2016.
Accessed on 10 October 2021.
Available:<https://patents.google.com/patent/US9314430B2/en>
107. Castan C, Caisse P. Controlled-release floating pharmaceutical compositions. US9561179; 2017.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US9561179B2/en>
108. Santus G, Bottoni G, Sala G. Pharmaceutical controlled-release composition with bioadhesive properties. US5472704; 1995.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US5472704A/en>
109. Rault I, Pichon G. Mucoadhesive pharmaceutical composition for the controlled release of active principles. US5900247; 1999.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US5900247A/en>
110. Gilis PMV. Bioadhesive solid dosage form. US6303147; 2001.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US6303147B1/en>
111. Dettmar PW, Dickson PA, Hampson FC, Jolliffe IG, Peers W. Mucoadhesive granules of carbomer suitable for oral administration of drugs. US6306789; 2001.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US6306789B1/en>
112. Jahagirdar HA, Kulkarni R, Kulkarni S. Pharmaceutical compositions for gastrointestinal drug delivery. US8974825; 2015.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US8974825B2/en>
113. Gillian E, Ronald P. Gastric raft composition. US20050063980A1; 2005.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US20050063980A1/en>
114. Yawei N, Kenneth MY. In-situ gelation formation of pectin. US00677700B2; 2004.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US6777000B2/en>
115. Wong PL, Edgren DE. Gastric retaining oral liquid dosage form. US6635281; 2003.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US6635281B2/en>
116. Edgren DE, Jao F, Wong PL. Gastric retention dosage form having multiple layers. US6797283; 2004.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US6797283B1/en>
117. Mohammad H. Gastroretentive drug delivery system comprising an extruded hydratable polymer. US8586083; 2013.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US8586083B2/en>
118. Bakan DA, Jitprabhai W, Newhard SB, Wotzman MS. Gastroretentive dosage forms for doxycycline. US9119793; 2015.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US9119793B1/en>
119. Navon N, Moor E, Kirmayer D, Kluev E, Carni G. Carbidopa /Levodopa gastroretentive drug delivery. US20150366832; 2015.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US20150366832A1/en>
120. Kumar V, Ahmad S, Singh RB, Singla AK. Osmotic floating tablets. US20150231084; 2015.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US20150231084A1/en>
121. Kumar V, Ahmad S, Singh RB, Nayyar K, Mohan P. Stabilized Gastroretentive tablets of pregabalin. US20160338949; 2016.
Accessed on 12 October 2021.
Available:<https://patents.google.com/patent/US20160338949A1/en>
122. Menachem AV, Zalit I. Expandable gastroretentive dosage form. EP3148514; 2017.
Available:<https://patents.google.com/patent/EP3148514A1/en>

123. Pilgaonkar PS, Rustomjee MT, Gandhi AS. Gastroretentive dosage forms of GABA analogs. EP2575798; 2017. Available:<https://patents.google.com/patent/EP2575798B1/en>

© 2021 Gupta et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/81173>